Cargando…

Rifaximin Reduces Risk of All-Cause Hospitalization in Cirrhotic Liver Transplant Candidates with Hepatic Encephalopathy

In cirrhotic patients listed for liver transplantation (LT) with a history of hepatic encephalopathy (HE), rifaximin reduces the number of hospitalizations, but whether it influences the time to first hospitalization is unknown. Aims: to evaluate the time-dependent impact of rifaximin on the risk of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parisse, Simona, Lai, Quirino, Martini, Francesca, Martini, Alice, Ferri, Flaminia, Mischitelli, Monica, Melandro, Fabio, Mennini, Gianluca, Rossi, Massimo, Alvaro, Domenico, Ginanni Corradini, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647372/ https://www.ncbi.nlm.nih.gov/pubmed/37959336 http://dx.doi.org/10.3390/jcm12216871

Ejemplares similares

A Low Daily Intake of Simple Sugars in the Diet Is Associated with Improved Liver Function in Cirrhotic Liver Transplant Candidates
por: Parisse, Simona, et al.
Publicado: (2023)

Severity of Hepatocyte Damage and Prognosis in Cirrhotic Patients Correlate with Hepatocyte Magnesium Depletion
por: Parisse, Simona, et al.
Publicado: (2023)

Low serum magnesium concentration is associated with the presence of viable hepatocellular carcinoma tissue in cirrhotic patients
por: Parisse, Simona, et al.
Publicado: (2021)

Platelet-to-lymphocyte ratio in the setting of liver transplantation for hepatocellular cancer: A systematic review and meta-analysis
por: Lai, Quirino, et al.
Publicado: (2018)

The Propensity of the Human Liver to Form Large Lipid Droplets Is Associated with PNPLA3 Polymorphism, Reduced INSIG1 and NPC1L1 Expression and Increased Fibrogenetic Capacity
por: Ferri, Flaminia, et al.
Publicado: (2021)

Adult 10-year survivors after liver transplantation: a single-institution experience over 40 years
por: Lai, Quirino, et al.
Publicado: (2023)

New Diagnostic and Prognostic Models for the Development of Alcoholic Cirrhosis Based on Genetic Predisposition and Alcohol History
por: Mischitelli, Monica, et al.
Publicado: (2023)

Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
por: Tamai, Yasuyuki, et al.
Publicado: (2021)

Donor Small-Droplet Macrovesicular Steatosis Affects Liver Transplant Outcome in HCV-Negative Recipients
por: Ferri, Flaminia, et al.
Publicado: (2019)

Reduction in Gastrointestinal Cancers in Cirrhotic Patients Receiving Rifaximin vs Lactulose Only Therapy for Hepatic Encephalopathy
por: Patel, Ankoor H, et al.
Publicado: (2023)

Rifaximin in the treatment of hepatic encephalopathy
por: Iadevaia, Maddalena Diana, et al.
Publicado: (2011)

Acquired cow’s milk sensitization after liver transplant in an adult: “clinical implications” and future strategies
por: Caruso, C., et al.
Publicado: (2019)

Rifaximin, Microbiota Biology, and Hepatic Encephalopathy
por: Peleman, Cedric, et al.
Publicado: (2016)

Neurofilament Light Chain Protein in Plasma and Extracellular Vesicles Is Associated with Minimal Hepatic Encephalopathy and Responses to Rifaximin Treatment in Cirrhotic Patients
por: Fiorillo, Alessandra, et al.
Publicado: (2023)

Rifaximin as Treatment for Hepatic Encephalopathy: Some Considerations
por: Ridola, Lorenzo, et al.
Publicado: (2013)

Emergence of rifampin-resistant staphylococci after rifaximin administration in cirrhotic patients
por: Chang, Ji Young, et al.
Publicado: (2017)

Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy
por: Kimer, Nina, et al.
Publicado: (2014)

Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy
por: Jesudian, Arun B., et al.
Publicado: (2020)

Reduced Lysosomal Acid Lipase Activity in Blood and Platelets Is Associated With Nonalcoholic Fatty Liver Disease
por: Ferri, Flaminia, et al.
Publicado: (2020)

Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy
por: Bajaj, Jasmohan S., et al.
Publicado: (2013)

Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese
por: Nishida, Shinya, et al.
Publicado: (2019)

Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy
por: Hayakawa, Yuka, et al.
Publicado: (2022)

Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study
por: Lv, Xin-Yue, et al.
Publicado: (2020)

Weight Gain and De Novo Metabolic Disorders after Liver Transplantation
por: Lattanzi, Barbara, et al.
Publicado: (2019)

Optimization of long-term graft survival after liver transplantation: the role of donor age
por: Lai, Q, et al.
Publicado: (2011)

Donor-to-recipient gender match in liver transplantation: A systematic review and meta-analysis
por: Lai, Quirino, et al.
Publicado: (2018)

A New-Onset Rash in the Setting of Rifaximin Treatment for Hepatic Encephalopathy
por: Fritz, Cassandra D.L., et al.
Publicado: (2014)

Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy
por: Ballester, María-Pilar, et al.
Publicado: (2022)

Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients
por: Nakai, Masato, et al.
Publicado: (2022)

Sodium benzoate and rifaximin are able to restore blood-brain barrier integrity in he cirrhotic rats
por: Thabut, D, et al.
Publicado: (2015)

The Effect of 12 Weeks of β-Hydroxy-β-Methyl-Butyrate Supplementation after Liver Transplantation: A Pilot Randomized Controlled Study
por: Lattanzi, Barbara, et al.
Publicado: (2019)

CONUT Score Predicts Early Morbidity After Liver Transplantation: A Collaborative Study
por: Spoletini, Gabriele, et al.
Publicado: (2022)

Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study
por: Paik, Yong-Han, et al.
Publicado: (2005)

Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis
por: Wu, Dong, et al.
Publicado: (2013)

Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
por: Neff, Guy, et al.
Publicado: (2018)

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
por: Kaji, Kosuke, et al.
Publicado: (2017)

Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence
por: Hudson, Mark, et al.
Publicado: (2019)

Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy
por: Wang, Zhida, et al.
Publicado: (2018)

Recurrence of Hepatic Encephalopathy after TIPS: Effective Prophylaxis with Combination of Lactulose and Rifaximin
por: Seifert, Leon Louis, et al.
Publicado: (2021)

Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis
por: Cheng, Junxiong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t6rhgqttb3clg2k5tu9gvtut06